Publications
Publications

Tamoxifen—Reducing Breast Cancer Risks: Case Histories of Transformational Advances

By: Amar Bhidé, Srikant Datar and Katherine Stebbins
  • Format:Print
  • | Language:English
  • | Pages:19
ShareBar

Abstract

We describe the development of tamoxifen, considered a “gold standard” treatment for millions of breast cancer patients. Specifically, we describe breast cancer treatments before tamoxifen’s development; the initial development of tamoxifen from 1960 to 1973; tamoxifen’s adoption as an adjuvant breast cancer treatment between 1973 and 1985; and the extension of tamoxifen’s use to include preventative treatment, between 1986 and 2002.

Keywords

Health Care and Treatment; Technological Innovation; Innovation and Invention; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Governing Rules, Regulations, and Reforms

Citation

Bhidé, Amar, Srikant Datar, and Katherine Stebbins. "Tamoxifen—Reducing Breast Cancer Risks: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 20-134, July 2020. (Revised May 2024.)

About The Author

Srikant M. Datar

More Publications

More from the Authors